Welcome to our dedicated page for Intellia Therape news (Ticker: NTLA), a resource for investors and traders seeking the latest updates and insights on Intellia Therape stock.
Intellia Therapeutics, Inc. (NASDAQ: NTLA) is a clinical-stage biotechnology leader pioneering CRISPR/Cas9 gene editing therapies. This page serves as the definitive source for official company announcements, including clinical trial updates, regulatory milestones, and strategic partnerships.
Investors and researchers will find curated press releases detailing NTLA's progress in treating genetic disorders like hereditary angioedema and ATTR amyloidosis. Content spans therapeutic pipeline developments, intellectual property advancements, and collaborative research initiatives with industry partners.
All materials are organized to facilitate quick scanning of critical updates while maintaining technical accuracy. Regular updates ensure stakeholders stay informed about NTLA's work in precision gene editing without promotional bias.
Bookmark this page for direct access to Intellia's latest financial reports, scientific publications, and conference participation details. Check back frequently for real-time updates on CRISPR-based therapeutic innovations.
Intellia Therapeutics has received regulatory approval from the UK Medicines and Healthcare products Regulatory Agency for a protocol amendment in its Phase 1 study of NTLA-2001, a CRISPR/Cas9-based therapy. The amendment allows enrollment of patients with ATTR amyloidosis with cardiomyopathy (ATTR-CM). The study aims to assess safety and efficacy, expanding its participant pool to include up to 36 adults with different forms of ATTR-CM. NTLA-2001 is pioneering as a potentially curative treatment, with previous interim data showing significant TTR level reductions.
Intellia Therapeutics (NASDAQ: NTLA) announced it will present data from its ex vivo research and development at the 63rd American Society of Hematology Annual Meeting, from December 11-14, 2021. Key presentations include a novel allogeneic technology that mitigates host cell rejection and details on the clinical-scale manufacturing of NTLA-5001, a T cell therapeutic for acute myeloid leukemia. The data aims to advance engineered cell therapies for life-threatening diseases, showcasing Intellia's commitment to CRISPR/Cas9 technology.
Intellia Therapeutics (NTLA) announced significant advancements in its clinical pipeline. They initiated dosing of Cohort 4 in the Phase 1 study of NTLA-2001, targeting ATTR amyloidosis, with data expected in Q1 2022. The company accelerated plans for NTLA-2001 in patients with ATTR-CM and is on track to launch first-in-human studies for NTLA-2002 (HAE) and NTLA-5001 (AML) by year-end. Intellia also nominated NTLA-3001 for AATD and reported a robust cash position of $1.1 billion. However, the company faced a net loss of $71.6 million in Q3 2021.
Intellia Therapeutics (NASDAQ: NTLA) will present its third quarter 2021 financial results and operational highlights on November 4, 2021, at 8 a.m. ET. The call can be accessed via U.S. dial-in at 1-833-316-0545 or international at 1-412-317-5726. It will feature crucial insights on the company's advancements in developing curative CRISPR/Cas9 therapeutics. Additionally, a replay will be available on the company's Investors & Media section after the call.
Intellia Therapeutics (NASDAQ: NTLA) announced that the FDA granted orphan drug designation to NTLA-2001 for treating ATTR amyloidosis. This investigational therapy is the first CRISPR treatment designed for systemic use. NTLA-2001 aims to be a potential single-dose treatment, possibly halting the disease’s complications. Intellia is committed to advancing its genome editing platform, with NTLA-2001 currently in Phase 1 trials. The FDA's designation provides development incentives, echoing a similar approval from the European Commission earlier this year.
Intellia Therapeutics (NASDAQ:NTLA) recently showcased significant preclinical advancements in its CRISPR/Cas9 genome editing platform at the ESGCT Annual Congress. Key highlights included the development of immune-evading allogeneic T cells, effective lipid nanoparticle delivery methods, and successful gene therapy results in non-human primates for treating alpha-1 antitrypsin deficiency (AATD). These findings support the company's strategy to progress its therapeutic candidates, including NTLA-5001 for acute myeloid leukemia, set to initiate clinical trials by year-end.
Intellia and SparingVision have announced a strategic collaboration to utilize Intellia's CRISPR/Cas9 technology for developing ocular therapies targeting three significant diseases. Intellia will grant SparingVision exclusive rights to its technology, receiving a 10% equity stake and potential milestone payments of up to $200 million per product. Additionally, Intellia may secure US commercialization rights for two targets. The collaboration aims to leverage both companies' strengths in genomic medicine and address unmet medical needs in ophthalmology. An investor webcast will provide further details.
Intellia Therapeutics (NASDAQ:NTLA) has presented key findings at the 29th Annual Congress of the European Society of Gene & Cell Therapy. The company showcased its proprietary allogeneic T cell therapy platform designed to address immune rejection in therapeutic candidates for cancer and autoimmune diseases. Significant advancements include a lipid nanoparticle-based CRISPR/Cas9 delivery system and the first reported consecutive in vivo gene insertion and knockout in non-human primates aimed at treating alpha-1 antitrypsin deficiency (AATD). This work positions Intellia at the forefront of genome editing therapeutics.
Intellia Therapeutics has received authorization from New Zealand's MEDSAFE to initiate a Phase 1/2 clinical study for NTLA-2002, a CRISPR/Cas9-based therapeutic aimed at treating hereditary angioedema (HAE). NTLA-2002 is designed to inactivate the KLKB1 gene, potentially providing a one-time treatment to prevent debilitating attacks associated with HAE. Patient enrollment is expected to start by year-end, with further regulatory applications planned globally. The program builds on insights gained from previous trials on NTLA-2001 for ATTR amyloidosis.
Intellia Therapeutics (NASDAQ:NTLA) will present at Chardan’s 5th Annual Genetic Medicines Conference on October 4, 2021, at 10:30 a.m. ET. This clinical-stage genome editing company is focused on developing curative therapeutics using CRISPR/Cas9 technology through in vivo and ex vivo methods. A live webcast of the presentation will be available on their website approximately 15 minutes prior to the start. A replay will be accessible for 14 days following the event.
